ISHITA DRUGS & INDUSTRIES LTD.Corp.   Off.:  401.   3rd   Eye   11,  Opp.  Parimal   Garden,   C.   G.   Road,  Ahmedabad-380006
Regd.   Owice    &    Factory    :    179/I.  Vasna-Iyava`   Tal     Sanand,   Disc.       Ahmedabad
E-mail  :isb±±adr±±gs@gmail.com   I   lnfo®ishitadrugs.com    I  URL  :www.ishitadrugs.corD
Phone  :  +91   7226995613/ 14/ 15 I    +9179  4002  3839
Date: 20.11.2025
To,
Department of Corporate Services,
BSE Limited.
Floor No. 25, Phiroze )eejeebhoy Towers,
Dalal Street, Mumbai- 400 001
Scril. Code: 524400
Dear Sir/Madam,
Sub: Disclosure under regulation 29(2] of sEB[ (Substantial Acq_ui§ition of Shares and
Takeoversl Ren]latious. 2011
With Reference to the captloned subject, please find enclosed the disclosure und'er regulation 29(2)
of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011:
a)           Acquisition of 114 shares of Rs.10/-each by lshita pharmaceuticals, related party of lshita
Drugs and Industries Ltd.
Please take the above disclosure on record.
Thanking You,
For, [shita Drugs and Industries Limited
Abha Agrawal
Director
uOuT 6astc i:ngs trt the servue Of hurnamty worttundcD
CIN  No. L24231 GJ 1992PLC017054
D a  a  D-U-N-S Number -65-018-0359

HsffiITyffi pffiffiREffi©yEuryE©ffiH£Phone: 91 -79 -26468353/7886, Email: harmal980 mail.com
Factory: 65/1, GIDC Industrial Estate, Wadhawan -363035, Surendranagar,  India.
Date: 19.11.ZOZ5
Scrin Code: 524400
isition of Sllar
To,
Department of Corporate Services,
BSE Limited.
Floor No. 25, Phiroze ]eejeebhoy Towers,
Dalal Street, Mumbai-400 001
[shita Drugs & Industries Ltd,
Office No: 401, 3rd Eye ||,
Opp. Parimal Garden, C.G. Road,
Ahmedabad - 380 006
Ihar Sir/Madam,
Sub: Disclosure under regulation 29f21 of SEBI rsubstantia
takeo\rers` Reflulations. 2011
With Reference to the captloned subject, lshita Pharmaceuticals, related party of Ishita Drugs and
Industries  Limited,  do  hereby inform you that we  have acquired  114 shares  of Rs.  10/-  each  of
lshita Drugs & Industries Ltd.
Please  find  enclosed  the  necessary  disclosure  as  required  under  regulation  29(2)  of  the  SEBI
(Substantial Acquisition of shares and Takeovers) Regulations, 2011.
Kindly, take the above information on your record.
Thankingyou,
Yours Faithfully,

HsffiITffi pffifflREffi©yEurE©yifersPhone: 91 -79 -26468353/7886, Email: harmal980 mail.com
Factory: 65/1, GIDC Industrial  Estate, Wadhawan -363035, Surendranagar, India.
Format for disclosures under ReE!ulation 29r21 Of SEBI /Substantiaal Acquisition Of Shares
andTakeoverslReguulations.2011
Name of the Target Company (TC) Ishita Drugs and Industries Limited
Name(s)   of  the  acquirer  and  Persons  Acting  in ]shita Pharmaceuticals
Concert fpAcl with the acquirer
Whether          the          acquirer          b elongs          to Related Party of the Tanget Company
Promoter/ Promoter group
Name(s)   of   the   Stock   Exchange(s)   where   the BSE Limited
shares ofTC are Listed
Details of the acquisition / disposal as follows Number % w.r.t. totalshare/votingcapitalwhereverapplicabler*1% w.r.t. totaldilutedshare/votingcapitaloftheTC(**)
Before the acquisition under consideration,
26285 0.88 0.88holding Of :
a)   Shares carrying votingrights
b)   Shares in the nature of encumbrance NilNil NilNil NilNil
(pledge/ lien/ non-disposal undeltaking/
others)
c)    Voting rights OVR) otherwise than by
shares
d)   Warrants/convertible          securities/any Nil26285 Nil0.88 Nil0.88other    instrument    that    entitles     the
acquirer to receive shares carrying voting
rights in the T C  (specify holding in each
category)
e)    Total (a+b+c+d)

ESEflITife EDHLifeRE©EuITE©ffiH£Phone: 91 -79 -26468353/886, Email:  ishitaiJharmal980@gmailcom
Factory: 65/1, GIDC Industrial Estate, Wadhawan -363035, Surendranagar,  India.
Details of acquisition
114 0.00 0.00a)    Shares          carrying         voting          rights
acquired/soid
b)   VRs   acquired   /sold   otherwise   than   by Nil Nil Nilshares
c)   Warrants/convertible          securities/any NilNil NilNil NilNilother     instrument     that     entitles     the
acquirer to receive shares carrying voting
rights  in the  TC  (specify  holding in  each
category) acquired/sold
d)   Shares encumbered / invoked/released by
the acquirer 114 0.00 0.00e)    Total fa+b+c+dl
After the acquisition, holding of:
26399 0.88 0.88a)    Shares carrying votingrights
b)   Shares encumbered with the acquirer NIL NIL NIL
c)   VRs otherwise than by shares NIL N]IJ I NIL
d)   Warrants/convertible         securities/any NIL2.6399 NIL0.88 NIL0.88
other    instrument    that    entitles     the
acquirer to receive shares carrying voting
rights in the TC  (specify holding in  each
category) after acquisition
e)   Total (a+b+c+d)
Mode of acquisition Open Market
Date of acquisition November 19, 2025
Equity share capital of the Target Company before Rs. 29903000/-(2990300 shares of Rs.10 each)
the said acquisition
Equity share  capital  of the  Target  Company after Rs. 29903000/-(2990300 shares of Rs.10 each)
the said acquisition
Total  diluted  share/voting  capital  of  the  Target Rs. 29903000/-(2990300 shares of Rs.10 each)
Company after the said acquisition
(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the
Stock Exchange under Clause 35 of the listing Agreement.
(**)   Diluted  share/voting  capital  means  the  total  number  of  shares  in  the  TC  assuming  full
conversion of the outstanding convertible securities/warrants into equity shares of the TC.
For lshita

